Home > Focus Areas > Migraine Connect > Post
  • Saved

3yr
A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine

A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine

Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722000816?via=ihub

Prior to the approval of , (onabot A) was the only Food and Drug Administration-approved erenumab onabotulinum toxin A chronic migraine preventive treatment. In this study, we assess the safety and efficacy of the combination of erenumab and onabot A for chronic migraine prevention.


Conclusion: This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.

  • 3yr
    Migraine is a common disabling primary headache disorder with high prevalence and significant socioeconomic burden and personal impacts.
  • 3yr
    We need to have this validated so that insurances are more open to covering it.
  • 3yr
    Key Points
    • Source: Clinical Neurology and Neurosurgery
    • Conclusion: “This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.”
    • Onabotulinum toxin A (Onabot A) was the only FDA-approved preventive treatment for migraine before the approval of erenumab.
    • When erenumab and onabot A were co-administered in 50 patients, there was a significant drop in monthly migraine days vs onabot A use alone. Similarly, monthly headache days also dropped. No severe adverse effects were noted.
    • Limitations of the current study include its small sample size, as well as real world and retrospective design.

Show More Comments

You might also like